(Q34773911)

4 August 2017

1 reference

title

Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin (English)

1 reference

4 August 2017

1 reference

Michael Igel

1

1 reference

4 August 2017

Thomas Sudhop

series ordinal

2

1 reference

4 August 2017

Klaus von Bergmann

series ordinal

3

1 reference

4 August 2017

publication date

1 August 2002

1 reference

The Journal of Clinical Pharmacology

4 August 2017

published in

1 reference

4 August 2017

volume

42

1 reference

4 August 2017

issue

8

1 reference

4 August 2017

page(s)

835-845

1 reference

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Rhabdomyolysis and HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Baycol withdrawn from market

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

NK-104: a novel synthetic HMG-CoA reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

A receptor-mediated pathway for cholesterol homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Comparison of statins in hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Coronary Plaque Disruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Importance of endothelial function in mediating the benefits of lipid-lowering therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Statins do more than just lower cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAYw6228, and its inhibitory effect on vascular smooth muscle cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Rho GTPases and signaling networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Rho GTPases and the actin cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

The IL-1 receptor and Rho directly associate to drive cell activation in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Acute-phase proteins and other systemic responses to inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Inflammation markers and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

C-reactive protein, inflammation, and coronary risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Homocysteine and coronary risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Homocysteine, B vitamins, and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Association of plasma homocysteine with the number of major coronary arteries severely narrowed

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

High-dose simvastin (80 mg/day) decreases plasma concentrations of total homocyst(e)ine in patients with hypercholesteromia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Decreased rate of coronary restenosis after lowering of plasma homocysteine levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Cytochrome P-450 3A4: regulation and role in drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

"It's the genes, stupid". Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Recent Advances: the Cytochrome P450 Enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Statin-fibrate combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Clinical pharmacokinetics of fibric acid derivatives (fibrates).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Current perspectives on statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Learning from the cerivastatin experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

A Quantitative Assessment of Plasma Homocysteine as a Risk Factor for Vascular Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Relationship between baseline risk factors and coronary heart disease and total mortality in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Preclinical review of cerivastatin sodium--a step forward in HMG-CoA reductase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Novel approaches to lipid lowering: what is on the horizon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Prospective evaluation of a stiff shaft glide wire compared with the standard straight wire in crossing severely stenotic aortic valves

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

HMG-CoA Reductase Inhibitors Decrease CD11b Expression and CD11b-Dependent Adhesion of Monocytes to Endothelium and Reduce Increased Adhesiveness of Monocytes Isolated From Patients With Hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Biotransformation of pravastatin sodium (I). Mechanisms of enzymic transformation and epimerization of an allylic hydroxy group of pravastatin sodium

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Clinical pharmacokinetics of pravastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Rhabdomyolysis associated with simvastatin-gemfibrozil therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Rhabdomyolysis after taking atorvastatin with gemfibrozil

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Plasma concentrations of active simvastatin acid are increased by gemfibrozil

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Lovastatin, nicotinic acid, and rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. Cerivastatin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Long-term efficacy and safety of cerivastatin 0.8 mg in patients with primary hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

First systematic chiral syntheses of two pairs of enantiomers with 3,5-dihydroxyheptenoic acid chain, associated with a potent synthetic statin NK-104

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Hokuriku NK-104 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102731

10.1177/009127002401102731

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference